Skip to main content
Premium Trial:

Request an Annual Quote

Samuel Zalipsky, John Berriman

Premium
Intradigm has named Samuel Zalipsky as its vice president of technology development.
 
Intradigm said he will be responsible for overseeing the company’s continued development of its nanoparticle-based RNAi delivery technology, as well as novel RNAi drug formulations. Salipsky will also handle Intradigm’s new technology development and in-licensing efforts.
 
Zalipsky has previously held positions with Alza, Sequus Pharmaceuticals, and Enzon.
 

 
Pronota, a Belgian predictive biomarker firm, has named John Berriman as its chairman.
 
Berriman was previously a director of Alnylam Pharmaceuticals.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.